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gemcitabineOnconase® (ONC) is a member of the RNase super-family that is secreted in oocytes and early embryos of Rana
pipiens. Over the last years, research interest about this small and basic frog RNase, also called ranpirnase, con-
stantly increased because of its high cytotoxicity and anticancer properties. Onconase is currently used in clinical
trials for cancer therapy; however, the precise mechanisms determining cytotoxicity in cancer cells have not yet
been fully investigated. In the present manuscript, we evaluate the antitumoral property of onconase in pancre-
atic adenocarcinoma cells and in non-tumorigenic cells as a control. We demonstrate that ONC stimulates a
strong antiproliferative and proapoptotic effect in cancer cells by reporting for the ﬁrst time that ONC triggers
Beclin1-mediated autophagic cancer cell death. In addition, ONC inhibits the expression of mitochondrial
uncoupling protein 2 (UCP2) and of manganese-dependent superoxide dismutase (MnSOD) triggering
mitochondrial superoxide ion production. ONC-induced reactive oxygen species (ROS) are responsible for Akt/
mTOR pathway stimulation determining the sensitivity of cancer cells to mTOR inhibitors and lessening autoph-
agic stimulation. This indicates ROS/Akt/mTOR axis as a strategy adopted by cancer cells to reduce ONC-mediated
cytotoxic autophagy stimulation. In addition, we demonstrate that ONC can sensitize pancreatic cancer cells to
the standard chemotherapeutic agent gemcitabine allowing a reduction of drug concentration when used in
combination settings, thus suggesting a lowering of chemotherapy-related side effects. Altogether, our results
shed more light on the mechanisms lying at the basis of ONC antiproliferative effect in cancer cells and support
its potential use to develop new anticancer strategies.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Onconase (ONC, see Fig. 1A) is a highly cytotoxic member of the
pancreatic-type ribonuclease (RNase) super-family [1] earlier named
P-30 protein [2] but known as ranpirnase or onconase® (ONC, Alfacell
Corporation, Somerset, NJ, USA). ONC is a monomer secreted in oocytes
and early embryos of Rana pipiens and shares 30% sequence identity
with the prototype RNase A even though it is smaller and more basic
than the latter (104 residues versus 124, and pI 9.7 versus 9.3, respec-
tively) [1–3]. ONC speciﬁcally evades the interaction with the cytosolic
ribonuclease inhibitor (RI) owing to its particular structure which
lacks the RNase A key-loop residues involved in the interaction with
RI [4–6]. Such a capacity confers to ONC a high cytotoxic activity against
several human cancer cell types, such as glioma cells [7] or lymphoma B
cells [8]. Notably, ONC is currently used in Phase II and Phase IIIb clinicaloduction Sciences, Biochemistry
4, Verona, Italy. Tel.: +39 045
delli).trials as therapy against non–small cell lung cancer and against
unresectable malignant mesothelioma, respectively [9]. In addition to
its anticancer properties, ONC is known to assume relevant roles as an
anti-viral enzyme which inhibits HIV-1 virion production within viable
replicating cells by degrading viral RNA and tRNALys [10,11].
Over the last years, autophagy has acquired an increasing relevance
in cancer research [12]. It is a highly conserved cellular process inwhich
cytoplasmic materials and organelles are sequestered into double-
membrane autophagic vesicles called autophagosomes and delivered
to lysosomes for degradation. This phenomenon occurs in response to
environmental conditions or cellular stimuli, such as starvation [13],
endoplasmic reticulum stress, and increased reactive oxygen species
(ROS) [14,15]. Besides having a cytoprotective role in cellular homeo-
stasis by acting as a cytoplasmic quality control mechanismwhich elim-
inates old or unfolded proteins and damaged organelles [16,17],
autophagy can also be a form of programmed cell death, designated as
“autophagic cell death” [18]. Then, the source of the lysosomal enzymes
used for degradation of dying cells is one of the elements that distin-
guish apoptosis from autophagic cell death. The induction of several
genes, including microtubule-associated protein 1 light chain 3 (LC3),
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Fig. 1. Effect of ONC on growth inhibition and apoptosis in pancreatic cancer cell lines (Panc1 and PaCa44) and in non-tumoral cells (ﬁbroblasts and HaCaT). (A) ONC structure (pdb code
1ONC): the residues of the catalytic triad are highlighted. (B) Cell growth determined with the crystal violet colorimetric assay. (C) Apoptosis analyzed using the annexin V/FITC binding
assay. In both (B) and (C) panels, cells were seeded in 96-well plates, incubated overnight, and treated with increasing concentrations of onconase for 72 h. Values are means (±SD) of
three independent biological replicates, each performed using three technical replicates (three wells).
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for the formation, maturation, and fusion of autophagic vesicles to
lysosomes [19]. Furthermore, autophagy incorporates signaling
through a different cellular pathway including the metabolic master
regulators mammalian target of rapamycin (mTOR) and adenosine
monophosphate-activated protein kinase (AMPK) [20].
Since the importance of the cytotoxic potential of some RNases
belonging to the secretory pancreatic-type RNase super-family
deﬁnitely increased in the last two decades, we investigated the effects
of ONC on cells of human pancreatic adenocarcinoma, which is a
particularly aggressive and devastating cancer type [21] characterized
by chemoresistance to traditional therapeutic drugs including treat-
ment with the gold standard nucleotide analogue gemcitabine (GEM;
2′,2′-diﬂuoro-2′-deoxycytidine) [22,23]. In particular, we aimed to ex-
plore the link between autophagy, ROS, and the antitumor activity of
ONC by investigating whether this cytotoxic enzyme may trigger
chemosensitivity of pancreatic adenocarcinoma cells to GEM.2. Materials and Methods
2.1. Chemicals
Recombinant onconase was produced and puriﬁed from E. coli,
extracted from inclusion bodies, and then refolded as previously
described [24]. Chloroquine diphosphate [CQ; N4-(7-chloro-4-
quinolinyl)-N1,N1-dimethyl-1,4-pentanediamine], 3-methyladenine
(3MA), N-acetyl-L-cysteine (NAC), and everolimus (EVE; RAD-001)
were obtained from Sigma (Milan, Italy). Gemcitabine (2′,2′-diﬂuoro-
2′-deoxycytidine; GEM) was provided by Accord Healthcare (Milan,
Italy) and solubilized in sterile water.
2.2. Cell culture
Panc1 and PaCa44 human pancreatic adenocarcinoma cell lines
were grown in RPMI 1640 supplemented with 2 mM glutamine
551C. Fiorini et al. / Biochimica et Biophysica Acta 1853 (2015) 549–560(Life Technologies, Milan, Italy), 10% FBS, and 50 μg/ml gentamicin sul-
fate (BioWhittaker, Lonza, Bergamo, Italy). Normal primary ﬁbroblasts
(PromoCell, PBI, Milan, Italy) and HaCaT non-tumorigenic keratinocytes
were grown in DMEM supplemented with 2 mM glutamine (Life
Technologies, Milan, Italy), 10% FBS, and 50 μg/ml gentamicin sulfate.
All cell types were incubated at 37 °C with 5% CO2.
2.3. Cell proliferation assay
Cells were seeded in 96-well plates (2.5 × 103 cells/well) and, the
day after, at the times indicated in ﬁgure legends, they were incubated
with ONC and/or various compounds. At the end of the treatments,
cells were stained with a crystal violet solution (Sigma, Milan, Italy).
The dye was solubilized in PBS containing 1% SDS and photometrically
measured (A595 nm) to determine cell growth.
2.4. Apoptosis assay
Cells were seeded in 96-well plates (2.5 × 103 cells/well) and, the
day after, treated for 72 h with the various compounds at the indicated
concentrations. At the end of the treatment, cells were ﬁxed with 2%
paraformaldehyde in PBS at room temperature for 30min, thenwashed
twice with PBS and stained for 10 min in the dark at room temperature
with annexin V/FITC (BenderMedSystem,Milan, Italy) in binding buffer
(10 mM HEPES/HCl pH 7.4, 140 mM NaCl, and 2.5 mM CaCl2). Finally,
cells were washed with binding buffer solution and ﬂuorescence was
measured with a multimode plate reader (λexc 485 nm and λem
535 nm) (GENios Pro, Tecan, Milan, Italy). Values were normalized on
cell proliferation by crystal violet assay.
2.5. Monodansylcadaverine staining and autophagosome detection
To quantify the induction of autophagy, cells were incubated with
monodansylcadaverine (MDC; Sigma, Milan, Italy), a selective ﬂuores-
cent probe for autophagosome detection. Brieﬂy, cells were seeded in
96-well plates (2.5 × 103 cells/well) and treated with the various com-
pounds indicated in the ﬁgure legends. At the end of the treatments,
cells were incubated for 15 min in culture medium with 50 μM MDC
at 37 °C. After incubation, cells were washed with Hanks buffer
(20 mM Hepes pH 7.2, 10 mM glucose, 118 mM NaCl, 4.6 mM KCl,
and 1mMCaCl2) and ﬂuorescencewasmeasured by using amultimode
plate reader (λexc 340 nm and λem 535 nm) (GENios Pro, Tecan, Milan,
Italy). Values were normalized on cell proliferation by crystal violet
assay.
2.6. GFP-LC3 translocation and quantitative analyses
Cells were transfected with pEGFP-LC3B plasmid using Lipofecta-
mine 2000 (Life Technologies). After transfection, cells were treated
with 100 μg/ml onconase for 72 h prior to ﬁxation. Image acquisition
was performedwith a Leica ﬂuorescence microscope at 40×magniﬁca-
tion. To determine the percentage of cells showing GFP-LC3B puncta,
the number of green dots was counted in at least 150 cells from ran-
domly placed positions within each sample. Cells showing more than
10 dots have been considered autophagic cells.
2.7. Acridine orange staining and autolysosome detection
Cells (1.6 × 104) were grown on coverslips and treated with
onconase as indicated. To assess nuclear morphology, cells were incu-
bated with Hoechst at RT for 2 min. Cell staining was performed with
acridine orange (AO; Molecular Probes/Invitrogen) at a ﬁnal concentra-
tion of 5 μg/ml for a period of 10 min (37 °C, 5% CO2), according to the
protocol indicated by the manufacturer. After washing with PBS three
times, images were obtained using a Leica ﬂuorescence microscope at
40× magniﬁcation.To quantify autolysosome formation, cells untreated or treated
with onconase were stained with AO following the manufacturer's
instructions. Autolysosome formation was performed measuring
the red/green ﬂuorescence intensity ratio of AO staining (AO green
ﬂuorescence λexc 485 nm and λem 535 nm; AO red ﬂuorescence λexc
430 nm and λem 590 nm) in a multimode plate reader (GENios Pro,
Tecan, Milan, Italy). Values were normalized on cell proliferation by
crystal violet assay.
2.8. siRNA transfection and Beclin1 silencing
Exponentially growing cellswere seeded at a density of 2.5×103 cells/
well in 96-well plates for autophagosome assay and at 2.5 × 105 cells/
plate in 60 mm cell culture plates for protein extraction. Twenty-
four hours later, transfections were carried out with a speciﬁc small
interfering (si) RNA duplex targeting Beclin1 mRNA (5′-ACAGUG
AAUUUAAACGACAGCAGCU-3′ and 5′-AGCUGCUGUCGUUUAAAUUC
ACUGU-3′) and with a non-targeting negative control siRNA-CTRL
(5′-CAGUCGCGUUUGCGACUGG-3′) purchased by Life Technologies
(Monza MB, Italy). Cells were transfected with siRNAs at a ﬁnal con-
centration of 50 nM using Lipofectamine 2000 (Life Technologies) for
24 h. At the end of transfection time, the cell medium was changed
and cells were treated with onconase for 72 h.
2.9. Transient over-expression of UCP2 and MnSOD
Exponentially growing cells were seeded at a density of 5 × 103 cells/
well in 96-well plates. Twenty-four hours later, transfections were car-
ried out with a pCR3.1 expression vector containing the cDNA of
human MnSOD (kindly provided by Dr. Akashi, National Institute
of Radiological Sciences, Chiba, Japan) and/or with a pCMV expression
vector containing the human cDNA of UCP2 (OriGene Technologies,
Rockville, MD) using Lipofectamine 2000 (Life Technologies), according
to themanufacturer's instructions. Cells transfectedwith the empty vec-
tor were used as a negative control and behaved as the untransfected
cells (data not shown). Cells were incubated for 24 h and then treated
with onconase for the indicated period.
2.10. Immunoblot analysis
Cells were harvested, washed in phosphate-buffered solution, and
re-suspended in RIPA buffer (50 mM Tris–HCl pH 8.0, 150 mM NaCl,
1% Igepal CA-630, 0.5% Na-Doc, 0.1% SDS, 1 mM Na3VO4, 1 mM NaF,
2.5 mM EDTA, 1 mM PMSF, and 1× protease inhibitor cocktail). After
three freeze/thaw cycles and incubation on ice for 30 min, lysate was
centrifuged at 14,000 ×g for 10 min at 4 °C, and the supernatant used
for Western blotting. Protein concentration was measured with the
Bradford protein assay reagent (Pierce, Milan, Italy) using bovine
serum albumin as a standard. Protein extracts (50 μg/lane) were elec-
trophoresed through a 12% SDS-polyacrylamide gel and electroblotted
onto PVDF membranes (Merck-Millipore, Milan, Italy). Membranes
were incubated in blocking solution [5% BSA in TBST (50 mM Tris
pH 7.5, 0.9% NaCl, 0.1% Tween 20)] for 1 h at room temperature and
probed overnight at 4 °C, at 1:1000 ﬁnal ratio (where not differently
speciﬁed) with a rabbit monoclonal anti-LC3 (Cell Signaling, cat. no.
2775), a rabbit polyclonal anti-Beclin1 (GeneTex, cat. no. GTX113039),
a goat polyclonal anti-UCP2 (Abnova, cat. no. PAB7242), a mouse
monoclonal anti-MnSOD antibody (1:2000; Abcam, cat. no. AB16956),
a rabbit monoclonal anti-GAPDH (Cell Signaling, cat. no. 5174S),
rabbit monoclonal anti-phospho-Akt Ser473 and anti-Akt (Cell
Signaling, cat. no. 4060P and no. 9272S, respectively), a mouse mono-
clonal anti-phopsho-p70S6K Thr389 (Cell Signaling, cat. no. 9206S), or
a rabbit monoclonal anti-p70S6K (Cell Signaling, cat. no. 2708S).
Horseradish peroxidase conjugated anti-rabbit or anti-mouse IgGs,
1:8000 in blocking solution (Upstate Biotechnology, Milan, Italy),
were used to detect speciﬁc proteins. Immunodetection was carried
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Pharmacia Biotech, Milan, Italy) and recorded with a HyperﬁlmECL
(GE-Healthcare, Amersham Pharmacia Biotech). ECL results were
scanned and the amount of protein bands was quantiﬁed using
NIH Image J software (http://rsb.info.nih.gov/nih-image/) and nor-
malized to the amount of GAPDH detected in the same sample
extract.2.11. Analysis of ROS
The non-ﬂuorescent diacetylated 2′,7′-dichloroﬂuorescein (DCF-DA)
probe (Sigma), which becomes highly ﬂuorescent upon oxidation,
was used to evaluate intracellular ROS production. Cells were plated
in 96-well plates (5 × 103 cells/well) and treated with various
compounds 24 h later, as indicated in the legends to the ﬁgures. Then,
cells were incubated with 10 μM DCF-DA for 15 min at 37 °C, and
DCF ﬂuorescence was measured (λexc 485 nm and λem 535 nm) in a
multimode plate reader (GENios Pro, Tecan, Milan, Italy). Values
were normalized on cell proliferation by the crystal violet assay. To
evaluate mitochondrial superoxide (O2 •−) production, cells were incu-
bated at 37 °C for 15 min in a culture medium supplemented with
0.5 μM non-ﬂuorescent MitoSox Red probe (Molecular Probes,
Invitrogen). Cells were washed with Hanks buffer (20 mM Hepes
pH 7.2, 10 mM glucose, 118 mM NaCl, 4.6 mM KCl, and 1 mM CaCl2)
and ﬂuorescence was measured in a multimode plate reader
(λexc 430 nm and λem 590 nm). The probe is live-cell permeant
and is rapidly and selectively targeted to mitochondria where it be-
comes ﬂuorescent after oxidation by O2•−. The usage of 430±35 nmex-
citationwavelengths allowed us to selectively detectmitochondrial O2•−
and to strongly reduce the recognition of other oxidants (e.g., –OH,
ONOO.−). Values were normalized on cell proliferation by the crystal
violet assay.2.12. Drug combination studies
Drug combination studieswere performedusing the100 μg/ml:1 μM
ﬁxed concentration ratio of ONC:GEM, chosen on the basis of onconase
and gemcitabine IC50 mean values. Taking into account the drug
concentration ratios, the in vitro concentration ranges used were
5 μg/ml → 200 μg/ml for ONC and 50 nM → 2 μM for GEM.
Concerning onconase and everolimus combination studies, we used
the 10 μg/ml:1 μM (ONC:EVE) ﬁxed concentration ratio. The concen-
tration ranges used were 1 μg/ml → 100 μg/ml for ONC and
0.1 μM→ 10 μM for EVE. The combination index (CI) values were cal-
culated by the Chou–Talalay equation, which takes into account both
potency (IC50) and shape of the dose–effect curve, taking advantage
of the CalcuSyn software (Biosoft, Cambridge, UK). The general
equation for the classic isobologram is given by CI = (D)1/(Dx)1 +
(D)2/(Dx)2 + [(D)1 · (D)2]/[(Dx)1 · (Dx)2], where (Dx)1 and
(Dx)2 in the denominators are the doses (or concentrations) of D1
(drug 1) and D2 (drug 2) alone that induces x% growth inhibition,
whereas (D)1 and (D)2 in the numerators are the doses of drug 1
and drug 2 that in combination also inhibit x% cell growth
(i.e., isoeffective). CI b 1, CI = 1, or CI N 1 generally indicate synergis-
tic, additive, or antagonistic effect, respectively. CI/effect curves rep-
resent the CI versus the fraction (0 → 1) of cells killed by drug
combinations. Throughout all experiments, we obtained a linear cor-
relation coefﬁcient of r N 0.90.Table 1
IC50 values (± SD) of onconase treatment at 72 h.
Cell lines Panc1 PaCa44 HaCaT Fibroblasts
IC50 (μg/ml) 22.1 ± 0.6 47.9 ± 0.4 N200 N200
IC50 represents the concentration of onconase that is required for 50% cell growth
inhibition.2.13. Statistical analysis
ANOVA analysis was performed by GraphPad Prism 5 software.
P value b 0.05 was indicated as to be statistically signiﬁcant.3. Results
3.1. Onconase affects growth of pancreatic adenocarcinoma cells more
efﬁciently than normal cells
To analyze the effect and the associated molecular mechanisms
of ONC (Fig. 1A) on pancreatic adenocarcinoma cell growth, we
used cancer cell lines strongly resistant to standard chemotherapy, such
as Panc1 and PaCa44 [25]. Pancreatic cancer cells were highly sensitive
to ONC, with a ~60%–65% cell growth inhibition after treatment with
200 μg/ml of enzyme (Fig. 1B). Intriguingly, HaCaT non-tumorigenic
keratinocytes (ONC IC50 N 200 μg/ml) and normal primary ﬁbroblasts
(ONC IC50 N 200 μg/ml) were signiﬁcantly less affected by ONC than
cancer cells (ONC IC50 = 22.1 ± 0.6 μg/ml for Panc1 cells and 47.9 ±
0.4 μg/ml for PaCa44 cells) (Table 1 and Fig. 1B). According to cell prolif-
eration results, ONC strongly induced apoptosis in pancreatic cancer
cells, while non-tumoral cells were considerably less affected (Fig. 1C).
3.2. Onconase triggers Beclin1-mediated autophagy in cancer cells
To further characterize the biological events regulated by ONC in pan-
creatic adenocarcinoma cells, we investigatedwhether autophagymaybe
a mechanism involved in cell growth inhibition. Western blot analysis of
the autophagy-related protein LC3 revealed that ONC strongly induced
the expression of LC3-II, which is the phosphoethanolaminated and func-
tionally active form of the autophagosome protein LC3-I (Fig. 2A). Since
LC3-II translocation in autophagic vesicle membranes is required for
autophagosome formation, we analyzed GFP-LC3 localization by ﬂuores-
cence microscope before and after ONC treatment. We demonstrate that
ONC stimulated the formation of green puncta in the cytoplasm of 67%
of Panc1 cancer cells (Table 2), as it is representatively shown in Fig. 2B.
This result reveals the formation of intracellular autophagosomes,
which, after fusion with lysosomes, constitute acidic vesicular organelles
(AVOs) detectable by acridine orange (AO), a nucleic acid dye that accu-
mulates in acidic lysosomes. Indeed, since lysosomal enzymes function
optimally over a narrow range of acidic pH values, we subsequently
usedAO staining to evaluate lysosomal acidiﬁcation. Under lowpHcondi-
tions, the dye emits red light when excited by blue light. As shown in
Fig. 2C, the AO red ﬂuorescence was greatly induced in ONC-treated
cells. To eliminate the possibility that the increase of the red ﬂuorescent
signal might be due to AO cell loading enhancement, we calculated the
ratio ofﬂuorescent intensity from red andgreen channels in both untreat-
ed and ONC-treated cells. Our measurements conﬁrmed that ONC stimu-
lated lysosomal acidiﬁcation and autolysosome formation in cancer cells
(Fig. 2D). To further explore the autophagy pathway induced by ONC in
cancer cells, we performed Western blot analyses of the autophagy-
related protein Beclin1, which revealed that ONC induced Beclin1 expres-
sion (Fig. 2E). In addition, Beclin1 knockdown by siRNA transfection
strongly rescued both ONC-mediated Beclin1 increase (Fig. 2E) and
autophagosome formation induced by ONC (Fig. 2F), thus establishing
that Beclin1 plays a key role in the ONC-stimulated autophagy pathway.
3.3. Onconase-induced autophagy sustains apoptotic cell death in cancer cells
To investigate the role of autophagy on cancer cell response to ONC,
we used autophagy inhibitors, such as chloroquine (CQ) or 3-
methyladenine (3MA). We ﬁrst checked the efﬁciency of both of these
inhibitors to repress ONC-stimulated autophagy (Fig. 3A), without
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553C. Fiorini et al. / Biochimica et Biophysica Acta 1853 (2015) 549–560triggering cytotoxicity (Fig. 3B) and apoptosis (Fig. 3C) in cancer cells.
Importantly, we observed that both CQ or 3MA treatments strongly
blocked ONC-mediated apoptosis (Fig. 3D) and signiﬁcantly reducedTable 2
Percentage of Panc1 cells with GFP-LC3 puncta
quantiﬁed by analyzing the number of green
dots in the cells untreated (CTRL) or treated with
100 μg/ml onconase for 72 h. Data are shown as
the mean ± SD of 3 independent experiments.
Panc1
CTRL 14% ± 4%
ONC 67% ± 6%ONC-mediated cancer cell growth inhibition (Fig. 3E). Since ONC was
also able to stimulate autophagosome formation in normal ﬁbroblasts
and HaCaT cells, although at lower levels than in both Panc1 and
PaCa44 cancer cell lines (Table 3), we investigated whether this event
could play a role in ONC-related growth inhibition of these non-
tumoral cells. Interestingly, autophagy inhibitors failed to modify
ONC-mediated growth inhibition in normal cell types (Fig. 3F and G).
Altogether, these data indicate that autophagy stimulation constitutes
a fundamental prerequisite to powerfully inducing ONC-stimulated
apoptosis in cancer cells. However, as the recovery by CQ or 3MA
of ONC-induced cell growth inhibition is only partial, we cannot
exclude that ONC may also stimulate anticancer mechanisms different
from apoptosis and autophagy, for instance, for cell cycle arrest and
senescence.
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respectively. Panc1 cells were seeded and treated as described in (A). (F and G) Cell growth of HaCaT cells and ﬁbroblasts, respectively, determined with the crystal violet colorimetric
assay. Cells were seeded and treated as described in (A). In all panels, values are means (±SD) of three independent biological replicates, each performed using three technical replicates
(three wells).
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inhibiting UCP2 and MnSOD expression
To further explore the biological events involved in the regulation of
cancer cell proliferation induced by ONC, we investigated whether this
enzyme may regulate the redox status of cancer cells. Importantly,
Fig. 4A shows that ONC treatment strongly repressed the expression
level of both mitochondrial antioxidant uncoupling protein 2 (UCP2)Table 3
Autophagosome formation (fold induction ± SD) after treatment with 100 μg/ml
onconase for 72 h.
Cell lines Panc1 PaCa44 HaCaT Fibroblasts
CTRL 1 1 1 1
ONC 3.73 ± 0.67 4.76 ± 0.53 2.18 ± 0.19 1.48 ± 0.18and manganese-dependent superoxide dismutase (MnSOD). In addition,
ONC-treated cells showed higher levels of mitochondrial superoxide ion
production as compared to untreated cells (Fig. 4B). To functionally eval-
uate the role of UCP2 and MnSOD inhibition on ONC-mediated ROS
increase, we exogenously over-expressed UCP2 or MnSOD proteins
(Supplemental Fig. 1A and B). We demonstrate that the exogenous ex-
pression of both UCP2 and MnSOD quite totally reduced ONC-mediated
cytosolic ROS production (Fig. 4C), revealing that inhibition of both
UCP2 and MnSOD is a concerted crucial mechanism lying at the basis of
the pro-oxidant effect of ONC in cancer cells. To unravel the biological ef-
fect of ROS increase, we analyzed autophagosome formation and cancer
cell growth after treatment with ONC and/or the antioxidant molecule
NAC. Remarkably, we observed that, in the presence of non-toxic concen-
trations of NAC, autophagy by ONC was further increased (Fig. 4D).
According to the cell death feature of ONC-mediated autophagy stimu-
lation, NAC addition to ONC treatment further decreased cancer cell
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555C. Fiorini et al. / Biochimica et Biophysica Acta 1853 (2015) 549–560proliferation (Fig. 4E). Finally, to verify the antioxidant property of
NAC under the experimental conditions used here, we analyzed
ROS production after cell treatment with ONC and/or NAC (Fig. 4F):
NAC deﬁnitely reduced the amount of ROS produced by ONC alone.
Altogether, these data indicate that ROS induction is a mechanism
adopted by cancer cells to escape or moderate autophagic cell death in-
duced by ONC.
3.5. Autophagy inhibition by ROS occurs through Akt/mTOR axis stimulation
Since Akt/mTOR axis is amaster repressormechanism of autophagy,
we investigatedwhether autophagy inhibition by ROSoccurred through
ROS/Akt/mTOR axis stimulation after ONC treatment. We demonstratethat both Akt and p70S6K, the direct target of mTOR commonly used
to test its activity, were phosphorylated and activated by ONC and
that this stimulation was completely blocked after the addition of
NAC. This indicates that ROS induced by ONC stimulated the Akt/
mTOR pathway in cancer cells (Fig. 5A). To evaluate the functional
role of mTOR stimulation, we analyzed autophagy and cancer cell
growth after treatment with ONC and/or everolimus (EVE), a potent
mTOR inhibitor. We observed that the combined treatment ONC/EVE
strongly enhanced both autophagy (Fig. 5B) and cell growth inhibition
(Fig. 5C). To evaluate the synergistic effect of ONC/EVE combination,
we analyzed cell growth inhibition curves by using the dedicated speciﬁc
software CalcuSyn (seeMaterials andMethods). Dose-dependent analy-
ses performed with different concentrations of ONC and/or EVE showed
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Panc1 cancer cells, as revealed by the curve of the combination index (CI)
values versus the fraction (0→ 1) of cells killed by drug combination
(CI50 = 0.119; Fig. 5D). Taken together, these data demonstrate that
ROS production by ONC reduced autophagic cell death via Akt/mTOR
pathway stimulation, which can make cancer cells highly sensitive to
mTOR inhibitors.
3.6. Onconase and gemcitabine synergistically inhibit cancer cell growth
Since gemcitabine (GEM) is the standard chemotherapeutic drug
used to treat pancreatic adenocarcinoma, and since ROS production
[25] and autophagy [14] are molecular mechanisms involved in the re-
sponse of pancreatic adenocarcinoma cells to GEM, we exploredwhether the ONC/GEM combined treatment may synergistically induce
cancer cell growth inhibition. Fig. 6A shows that ONC treatment in com-
bination with GEM signiﬁcantly increased Panc1 cell growth inhibition,
as compared to single treatments. A similar effect has also been ob-
served in PaCa44 cells (Supplemental Fig. 2A). Dose-dependent analy-
ses performed with different concentrations of ONC and/or GEM
showed that the combined setting induced a relevant antiproliferative
synergism in Panc1 cancer cells, as revealed by the curve of the combi-
nation index (CI) values versus the fraction (0→ 1) of cells killed by
drug combination (Fig. 6B). In fact, the CI values lying below 1 arewide-
ly distributed in the x axis, indicating a synergistic effect occurring at
both low and high drug concentrations (Fig. 6B). A similar result has
also been observed in PaCa44 cells (Supplemental Fig. 2B). In particular,
CI25, CI50, and CI75 values for ONC/GEM combination were 0.041, 0.164,
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557C. Fiorini et al. / Biochimica et Biophysica Acta 1853 (2015) 549–560and 0.66, respectively, revealing that the antiproliferative synergism is
particularly pronounced at low concentrations of both compounds
(Fig. 6C). In addition, we show the reduction folds (dose reduction
index; DRI) of drug concentration to obtain 25%, 50%, or 75% cell growth
inhibition in combination settings as compared to each drug adminis-
tered alone (Fig. 6D). According to CIs, Fig. 6D shows values of
DRI25 N DRI50 N DRI75 for both compounds, conﬁrming a strong ONC/
GEMsynergismat lowdrug concentrations. Furthermore, GEMDRI valuesare higher than those obtained for ONC, indicating that treatment with
this ribonuclease enzyme is able to strongly promote chemosensitization
of pancreatic adenocarcinoma cells to standard chemotherapy. Finally,we
investigated if apoptosis, autophagy, and ROS production induced by sin-
gle drug treatments may be further enhanced by ONC/GEM combination.
Apoptosiswas strongly increased in the combined setting (Fig. 6E), while,
surprisingly, ROS production (Fig. 6F) and autophagy were not further
stimulated (Fig. 6G).
Fig. 7.Model of the molecular mechanisms identiﬁed in this study.
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schematically represented in Fig. 7, indicate that autophagy induced
by ONC (mediated by Beclin1 and repressed by ROS/Akt/mTOR axis) is
required for ONC-induced apoptosis. Furthermore, autophagy by ONC
was further induced by GEM addition promoting their synergistic inhi-
bition of pancreatic adenocarcinoma cell growth.4. Discussion
In the presentmanuscript, we demonstrate that ONC strongly affects
the proliferation of pancreatic adenocarcinoma cells, while it is signiﬁ-
cantly less active in normal and non-tumoral cells, as we previously ob-
served for bovine seminal RNase (BS-RNase) [26,27]. This result can be
explainedwith the higher capability of these RNases to interactwith the
very acidic membrane lipids of cancer cells than with those of normal
cells [28–30]. Furthermore, interaction of RNases with cell membrane
is augmented upon oligomerization increasing their basic charge densi-
ty [31–33] or when some key residues are mutated to more basic ones,
such as for G38K-BS-RNase [26,28].
Here, we show for the ﬁrst time that ONC antitumoral activity is me-
diated by autophagy stimulation. Autophagy is mainly regulated via a
group of highly conserved autophagy-related genes (Atg), among which
Beclin1 binds to the Class III phosphatidylinositol-3-kinase Vps34, which
generates the phosphatidylinositol-3-phosphate (PtdIns-3-P) required
for autophagosome formation [34]. Our results, obtained with knock-
down assay, reveal that Beclin1 (also called Atg6) is functionally involved
in the formation of autophagosomes induced by ONC. According to these
data, we previously demonstrated that BS-RNase triggers Beclin1-
dependent autophagic cell death in cancer cells providing evidence that
high proliferation rates of cancer cells may render themmore susceptible
to autophagy by BS-RNase treatment [26]. Moreover, autophagy varia-
tions in live cells can be monitored by using a GFP-fused LC3 protein
(GFP-LC3) analyzing the presence of GFP-LC3 puncta which rapidly
increase when autophagy is activated. Accordingly, we demonstrate
that ONC treatment strongly increases both LC3-green puncta and
autophagosomes in cancer cells. To demonstrate that autophagosome ac-
cumulation by ONC is due to autophagy induction, rather than to a block
in downstream steps, we observed that ONC increases red/green ratio
ﬂuorescence of acridine orange (AO) probe revealing the maturation of
autophagy during the ﬁnal steps. Intriguingly, we demonstrate that the
cytotoxic effect of autophagy stimulation induced by ONC is largely due
to the shifting of the autophagic process toward proapoptotic signals re-
vealed by the binding of annexin V-FITC to cancer cell membranes. We
observed that pharmacological autophagy inhibition by CQ or 3MA
strongly represses apoptosis induced by ONC, indicating that autophagy
is a fundamental event leading to apoptotic suicide of cancer cells. Indeed,
in some circumstances, autophagy can develop as a trigger of apoptosiswith a primary response to stress stimuli followed by the promotion of
either apoptotic or necrotic ﬁnal cell death [35].
Since ROS is a major stress stimulator of autophagy and a close rela-
tionship between ROS and autophagy exists [36], we investigated
whether ONC treatment also modulates ROS production. Notably, in
contrast to the unique publication describing an antioxidant effect of
ONC in the immortalized line of human T lymphocyte Jurkat cells [37],
we demonstrate for the ﬁrst time that ONC enhances mitochondrial su-
peroxide ion production through the inhibition of the expression of
both mitochondrial UCP2 and MnSOD, two of the most important anti-
oxidant systems ofmitochondria [38,39]. This suggests a possible differ-
ential regulation of the cellular redox status by ONC,whichmay depend
on the cellularmodel analyzed. However, we surprisingly observed that
ROS rescue, by adding the antioxidant NAC, further enhances autopha-
gic cell death by ONC, indicating that ROS acts as compensatory species
associated with a mechanism adopted by cancer cells in order to escape
or dramatically reduce cytotoxic autophagic stimulation. To explore the
mechanism underlying the anti-autophagic role of ONC-induced ROS,
we analyzed the activity of mTOR, one of the most powerful enzymatic
inhibitors of the autophagic pathway. Our data reveal for the ﬁrst time
that ONC strongly induces the cytosolic Akt/mTOR pathway in a ROS-
dependent manner. These results suggest that mitochondrial superox-
ide generated by ONC through inhibition of UCP2 and MnSOD expres-
sion may inﬂuence the cytosolic redox status of the cell. Indeed, UCP2
inhibition may enhance the mitochondrial membrane potential, thus
causing perturbations of respiratory chain function, electron leakage
from electron transport chain (ETC) and higher superoxide production
[38]. Since ONC treatment reduces the expression of both UCP2
and MnSOD, the mitochondrial superoxide ion conversion in the
membrane-permeable oxidant molecule H2O2 is, at least partially, re-
pressed. The stimulation of cytosolic ROS by ONCmay thus be explained
by observing that superoxide ions produced by electron leakage from
complex III of the respiratory chain can be released to both the matrix
and the intermembrane space where it can be converted to H2O2 by
Cu/ZnSOD and released into the cytosol [40,41]. In addition, some evi-
dence indicates that mitochondrial matrix-directed superoxide can be
released from the mitochondria through voltage-dependent anion
channels (VDAC) increasing cytosolic ROS generation [42]. Our results
demonstrate that cytosolic ROS induced by ONC can be quite totally res-
cued by exogenous expression of UCP2 and MnSOD and indicate that
mitochondrial superoxide production can be considered the main
source of ROS induced by ONC treatment.
In this study, we show that ROS generated by ONC can induce Akt/
mTOR pathway thus promoting chemosensitivity of cancer cells to-
wards mTOR inhibitors that are currently used in clinical trials as anti-
cancer agents [43]. Despite many studies showing that ROS generation
can inhibit Akt/mTOR pathway, there is, however, mounting evidence
demonstrating that mTOR pathway can be activated by ROS and that
559C. Fiorini et al. / Biochimica et Biophysica Acta 1853 (2015) 549–560the addition of antioxidants can prevent its stimulation [44–48]. Since
mTOR pathway, in addition to promoting protein synthesis, activates
speciﬁc bioenergetic and anabolic cellular processes that are likely to
contribute to human physiology and disease [49], our results can repre-
sent a ﬁrst step in the elucidation of the metabolic reprogramming of
cancer cells treated with RNases.
Furthermore, since GEM is the gold standard chemotherapeutic drug
in pancreatic adenocarcinoma treatment, we show that ONC association
with GEM synergistically inhibits pancreas cancer cell proliferation,
without further enhancing autophagy and ROS production but strongly
increasing apoptotic cell death. Intriguingly, pancreas cancer cell sensi-
tization to GEM treatment by ONC can determine a reduction of GEM
concentration when used in a combination setting, suggesting a lower-
ing of chemotherapy-related side effects in vivo.
5. Conclusions
Overall, the data presented here indicate that ONC strongly inhibits
pancreatic adenocarcinoma cell proliferation triggering Beclin1-
mediated autophagic cell death and sensitizing cancer cells to apoptotic
stimulation by GEM. Inhibition of the mitochondrial antioxidant pro-
teins UCP2 andMnSODdetermines a burst ofmitochondrial superoxide
and of cytosolic ROS responsible for Akt/mTOR pathway activation by
ONC, conferring, in turn, cancer cell sensitivity to mTOR inhibitors.
Finally, chemosensitization of cancer cells to GEM induced by ONC can
be considered as an encouraging therapeutic tool against pancreatic
adenocarcinoma.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.12.016.
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